{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:01:13Z","timestamp":1790215273140,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002418","name":"China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica","doi-asserted-by":"publisher","award":["2022-RC350-04"],"award-info":[{"award-number":["2022-RC350-04"]}],"id":[{"id":"10.13039\/501100002418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L248087"],"award-info":[{"award-number":["L248087"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372002"],"award-info":[{"award-number":["82372002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jconrel.2026.115260","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T14:10:33Z","timestamp":1786889433000},"page":"115260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An indocyanine green-potentiated gastrin releasing peptide receptor-targeting multifunctional peptide-drug conjugate for prostate cancer therapy"],"prefix":"10.1016","volume":"398","author":[{"given":"Hao","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangding","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengfu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10467","key":"10.1016\/j.jconrel.2026.115260_bb0005","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(24)01967-6","article-title":"Prostate radiotherapy in the era of intensified systemic treatment of metastatic prostate cancer","volume":"404","author":"Udovicich","year":"2024","journal-title":"Lancet"},{"issue":"10437","key":"10.1016\/j.jconrel.2026.115260_bb0010","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jconrel.2026.115260_bb0015","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.115260_bb0020","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.115260_bb0025","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.115260_bb0030","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.115260_bb0035","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2026.115260_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114993","article-title":"Toward targeting the untargetable: a non-canonical EGFR-peptide\u2013drug conjugate achieves potent antitumor activity in KRAS-mutant CRC","volume":"395","author":"Ayali","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115260_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117204","article-title":"Recent progress in the development of peptide-drug conjugates (PDCs) for cancer therapy","volume":"284","author":"He","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115260_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117131","article-title":"Navigating cancer therapy: harnessing the power of peptide-drug conjugates as precision delivery vehicles","volume":"283","author":"Sagar","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115260_bb0055","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1016\/j.apsb.2025.06.012","article-title":"A dual-targeting peptide\u2013drug conjugate based on CXCR4 and FOLR1 inhibits triple-negative breast cancer","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"21","key":"10.1016\/j.jconrel.2026.115260_bb0060","doi-asserted-by":"crossref","first-page":"23389","DOI":"10.1021\/acs.jmedchem.5c02183","article-title":"64Cu-labeled stapled peptide-based radiopharmaceuticals targeting MDM2\/MDMX for Pan-p53 tumors","volume":"68","author":"Tian","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115260_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70016","article-title":"Beyond efficacy: ensuring safety in peptide therapeutics through immunogenicity assessment","volume":"31","author":"Achilleos","year":"2025","journal-title":"J. Pept. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115260_bb0070","doi-asserted-by":"crossref","first-page":"9576","DOI":"10.1021\/jacs.4c17615","article-title":"Triazination\/IEDDA cascade modular strategy installing pyridines\/pyrimidines onto tyrosine enables peptide screening and optimization","volume":"147","author":"Zuo","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"21","key":"10.1016\/j.jconrel.2026.115260_bb0075","article-title":"Cysteine-specific multifaceted bioconjugation of peptides and proteins using 5-substituted 1, 2, 3-triazines","volume":"11","author":"Zuo","year":"2024","journal-title":"Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"10.1016\/j.jconrel.2026.115260_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2025.216765","article-title":"Diverse tyrosine modification strategies in peptides\/proteins and applications in radiopharmaceuticals","volume":"540","author":"Zuo","year":"2025","journal-title":"Coord. Chem. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115260_bb0085","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s41557-025-01896-8","article-title":"Immobilized acyl-transfer molecular reactors enable the solid-phase synthesis of sterically hindered peptides","volume":"17","author":"Wei","year":"2025","journal-title":"Nat. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115260_bb0090","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2967\/jnumed.120.258814","article-title":"GRPr antagonist 68Ga-SB3 PET\/CT imaging of primary prostate cancer in therapy-na\u00efve patients","volume":"62","author":"Bakker","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115260_bb0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrurol.2013.42","article-title":"Targeting GRPR in urological cancers\u2014from basic research to clinical application","volume":"10","author":"Mansi","year":"2013","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115260_bb0100","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.7150\/thno.22601","article-title":"68Ga-BBN-RGD PET\/CT for GRPR and integrin \u03b1v\u03b23 imaging in patients with breast cancer","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115260_bb0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-010-1596-9","article-title":"Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours","volume":"38","author":"Mansi","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115260_bb0110","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2967\/jnumed.123.265771","article-title":"Preclinical comparison of the 64Cu-and 68Ga-labeled GRPR-targeted compounds RM2 and AMTG, as well as first-in-humans [68Ga] Ga-AMTG PET\/CT","volume":"64","author":"Koller","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115260_bb0115","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3390\/cancers15072161","article-title":"Pre-and intraoperative visualization of GRPR-Expressing Solid tumors: preclinical profiling of Novel Dual-Modality probes for nuclear and fluorescence imaging","volume":"15","author":"Verhoeven","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115260_bb0120","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7150\/thno.91554","article-title":"Lower-grade gliomas surgery guided by GRPR-targeting PET\/NIR dual-modality image probe: a prospective and single-arm clinical trial","volume":"14","author":"Chen","year":"2024","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115260_bb0125","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","article-title":"Peptide\u2013drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?","volume":"13","author":"Fu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115260_bb0130","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00726-005-0289-3","article-title":"Strategies to improve plasma half life time of peptide and protein drugs","volume":"30","author":"Werle","year":"2006","journal-title":"Amino Acids"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115260_bb0135","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3390\/biom13071134","article-title":"Preclinical characterization of a stabilized gastrin-releasing peptide receptor antagonist for targeted cancer theranostics","volume":"13","author":"Abouzayed","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115260_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40644-024-00658-y","article-title":"Advances of radiolabeled GRPR ligands for PET\/CT imaging of cancers","volume":"24","author":"Ma","year":"2024","journal-title":"Cancer Imaging"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115260_bb0145","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1021\/acs.jmedchem.5c00007","article-title":"Recent advances in augmenting the therapeutic efficacy of peptide\u2013drug conjugates","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115260_bb0150","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41589-023-01496-y","article-title":"De novo development of small cyclic peptides that are orally bioavailable","volume":"20","author":"Merz","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"21","key":"10.1016\/j.jconrel.2026.115260_bb0155","doi-asserted-by":"crossref","first-page":"14623","DOI":"10.1021\/acs.jmedchem.3c01135","article-title":"Development of a 18F-labeled bicyclic peptide targeting EphA2 for molecular imaging of PSMA-negative prostate cancer","volume":"66","author":"Gan","year":"2023","journal-title":"J. Med. Chem."},{"issue":"28","key":"10.1016\/j.jconrel.2026.115260_bb0160","doi-asserted-by":"crossref","first-page":"8145","DOI":"10.1002\/ange.201602806","article-title":"An in-tether chiral center modulates the helicity, cell permeability, and target binding affinity of a peptide","volume":"128","author":"Hu","year":"2016","journal-title":"Angew. Chem."},{"issue":"46","key":"10.1016\/j.jconrel.2026.115260_bb0165","first-page":"42607","article-title":"De novo discovery of \u03b1, \u03b1-disubstituted \u03b1-amino acid-containing \u03b1-helical peptides as competitive PPAR\u03b3 PPI inhibitors","volume":"147","author":"Sigal","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115260_bb0170","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1039\/D0CP04633G","article-title":"Cyclic peptides: backbone rigidification and capability of mimicking motifs at protein\u2013protein interfaces","volume":"23","author":"Huang","year":"2021","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115260_bb0175","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1021\/acs.jmedchem.0c01766","article-title":"Bioactive cyclization optimizes the affinity of a proprotein convertase subtilisin\/kexin type 9 (PCSK9) peptide inhibitor","volume":"64","author":"Tombling","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115260_bb0180","doi-asserted-by":"crossref","first-page":"1806058","DOI":"10.1002\/adfm.201806058","article-title":"From nanofibers to nanorods: nanostructure of peptide-drug conjugates regulated by polypeptide-PEG derivative and enhanced antitumor effect","volume":"29","author":"Chen","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2026.115260_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113430","article-title":"Tumor vasculature-targeting PEGylated peptide-drug conjugate prodrug nanoparticles improve chemotherapy and prevent tumor metastasis","volume":"219","author":"Hao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115260_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100962","article-title":"Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents","volume":"48","author":"Kopp","year":"2024","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2026.115260_bb0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2018.04.013","article-title":"Tumor uptake of pegylated diabodies: balancing systemic clearance and vascular transport","volume":"279","author":"Li","year":"2018","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115260_bb0200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/1553350615604053","article-title":"Indocyanine green: historical context, current applications, and future considerations","volume":"23","author":"Reinhart","year":"2016","journal-title":"Surg. Innov."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115260_bb0205","doi-asserted-by":"crossref","DOI":"10.5761\/atcs.cr.25-00015","article-title":"Intraoperative fluorescent imaging with indocyanine green during thoracoscopic esophagectomy with subcarinal lymph node dissection for esophageal cancer with a right superior pulmonary vein anomaly: a case report and literature review","volume":"31","author":"Ujiie","year":"2025","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115260_bb0210","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1039\/D2BM01551J","article-title":"ICG-loaded and 125I-labeled theranostic nanosystem for multimodality imaging-navigated phototherapy of breast cancer","volume":"11","author":"Wang","year":"2022","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115260_bb0215","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12951-024-02431-6","article-title":"A pH-responsive nanoplatform with dual-modality imaging for enhanced cancer phototherapy and diagnosis of lung metastasis","volume":"22","author":"Yuan","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115260_bb0220","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ijc.30102","article-title":"Preferential tumor cellular uptake and retention of indocyanine green for in vivo tumor imaging","volume":"139","author":"Onda","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115260_bb0225","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.apsb.2021.09.016","article-title":"Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors","volume":"12","author":"Hu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115260_bb0230","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00259-024-06907-3","article-title":"Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: applications in PET imaging of multiple myeloma","volume":"52","author":"Ma","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"39","key":"10.1016\/j.jconrel.2026.115260_bb0235","doi-asserted-by":"crossref","first-page":"35638","DOI":"10.1021\/jacs.5c11292","article-title":"Multicyclic peptides targeting PD-L1 for radiotheranostics: from discovery to clinical proof-of-concept","volume":"147","author":"Cheng","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115260_bb0240","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","article-title":"Dosimetry of [177Lu] Lu-PSMA\u2013targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis","volume":"65","author":"Ells","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"13_Supplement","key":"10.1016\/j.jconrel.2026.115260_bb0245","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1158\/1538-7445.AM2018-5854","article-title":"BT5528, a Bicycle Toxin Conjugate targeting EphA2 has potent anti-tumor activity without bleeding or coagulation abnormalities in preclinical models","volume":"78","author":"Bennett","year":"2018","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115260_bb0250","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1021\/acs.molpharmaceut.3c00189","article-title":"Peptide\u2013drug conjugate targeting keratin 1 inhibits triple-negative breast cancer in mice","volume":"20","author":"Ziaei","year":"2023","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115260_bb0255","first-page":"1152","article-title":"Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation","volume":"59","author":"Markwalder","year":"1999","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115260_bb0260","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/pros.21434","article-title":"Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates","volume":"72","author":"Beer","year":"2012","journal-title":"Prostate"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:03:43Z","timestamp":1790211823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926006644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":52,"alternative-id":["S0168365926006644"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115260","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An indocyanine green-potentiated gastrin releasing peptide receptor-targeting multifunctional peptide-drug conjugate for prostate cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115260"}}